

Version 3.5      Revision Date: 09.04.2021      SDS Number: 402646-00013      Date of last issue: 10.10.2020  
Date of first issue: 07.01.2016

---

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Trade name : Olmesartan / Hydrochlorothiazide Formulation

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

215-631-6999

---

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A	H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P260 Do not breathe dust.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

## Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/attention.

**Storage:**

P405 Store locked up.

Hazardous components which must be listed on the label:

Olmesartan  
Hydrochlorothiazide

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Olmesartan	144689-63-4	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1A; H360D	>= 1 - < 10
Hydrochlorothiazide	58-93-5 200-403-3	STOT RE 1; H372 (Kidney, Parathyroid gland)	>= 1 - < 10

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty

## Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

- of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

**4.2 Most important symptoms and effects, both acute and delayed**

- Risks : May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.
- 

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Chlorine compounds  
Sulphur oxides

**5.3 Advice for firefighters**

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.

# Olmesartan / Hydrochlorothiazide Formulation

Version 3.5      Revision Date: 09.04.2021      SDS Number: 402646-00013      Date of last issue: 10.10.2020  
Date of first issue: 07.01.2016

Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Organic peroxides  
Explosives  
Gases

## 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Olmesartan	144689-63-4	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
Cellulose	9004-34-6	TWA OEL-RL (Respirable dust)	5 mg/m <sup>3</sup>	ZA OEL
Further information: Recommended Limit				
		TWA OEL-RL (inhalable dust)	10 mg/m <sup>3</sup>	ZA OEL

# SAFETY DATA SHEET



## Olmesartan / Hydrochlorothiazide Formulation



Version 3.5      Revision Date: 09.04.2021      SDS Number: 402646-00013      Date of last issue: 10.10.2020  
Date of first issue: 07.01.2016

Further information: Recommended Limit				
		STEL OEL-RL (Dust)	20 mg/m <sup>3</sup>	ZA OEL
Further information: Recommended Limit				
Hydrochlorothiazide	58-93-5	TWA	100 µg/m <sup>3</sup> (OEB 2)	Internal

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type (P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

- Appearance : powder
- Colour : white to off-white
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

## 9.2 Other information

Flammability (liquids)	:	No data available
Molecular weight	:	Not applicable
Particle size	:	No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means.
---------------------	---	---

## Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

dling or other means.  
Can react with strong oxidizing agents.

**10.4 Conditions to avoid**

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

**10.5 Incompatible materials**

Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

**Components:****Olmesartan:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
LD50 (Mouse): > 2.000 mg/kg  
LD50 (Dog): > 1.500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**Hydrochlorothiazide:**

Acute oral toxicity : LD50 (Rat): > 2.750 mg/kg  
LD50 (Mouse): > 2.830 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg  
Application Route: Intravenous

LD50 (Mouse): 590 mg/kg  
Application Route: Intravenous



## Olmesartan / Hydrochlorothiazide Formulation

Version 3.5      Revision Date: 09.04.2021      SDS Number: 402646-00013      Date of last issue: 10.10.2020  
Date of first issue: 07.01.2016

---

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Olmesartan:**

Remarks : No data available

**Hydrochlorothiazide:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Olmesartan:**

Species : Rabbit  
Method : Draize Test  
Result : Moderate eye irritation

**Hydrochlorothiazide:**

Species : Rabbit  
Result : Mild eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Olmesartan:**

Exposure routes : Skin contact  
Remarks : No data available

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Olmesartan:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)  
Result: negative

Test Type: Chromosome aberration test in vitro

## Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

		Test system: Chinese hamster lung cells Result: positive
		Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Hydrochlorothiazide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
		Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells Result: positive
		Test Type: in vitro assay Test system: mouse lymphoma cells Result: positive
Genotoxicity in vivo	:	Test Type: Chromosomal aberration Species: Chinese hamster Cell type: Bone marrow Result: negative
		Test Type: in vivo assay Species: Mouse Cell type: Bone marrow Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Olmesartan:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Result	:	negative

## Olmesartan / Hydrochlorothiazide Formulation

Version 3.5      Revision Date: 09.04.2021      SDS Number: 402646-00013      Date of last issue: 10.10.2020  
 Date of first issue: 07.01.2016

---

Species : Mouse  
 Application Route : Oral  
 Exposure time : 6 Months  
 Result : negative

**Hydrochlorothiazide:**

Species : Mouse, female  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

Species : Mouse, male  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : equivocal

Species : Rat, male and female  
 Application Route : Oral  
 Exposure time : 2 Years  
 Result : negative

**Reproductive toxicity**

May damage the unborn child.

**Components:****Olmesartan:**

Effects on fertility : Test Type: Fertility  
 Species: Rat  
 Application Route: Oral  
 Fertility: NOAEL: 1.000 mg/kg body weight  
 Result: No effects on fertility

Effects on foetal development : Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Dose: 1000 milligram per kilogram  
 Result: No teratogenic effects

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Dose: 1 milligram per kilogram  
 Result: No teratogenic effects

Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: >= 1,6 mg/kg body weight  
 Symptoms: Malformations were observed., Reduced body weight  
 Result: Effects on postnatal development

## Olmesartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

**Hydrochlorothiazide:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 4 mg/kg body weight  
Result: Effects on fertility

Test Type: Fertility  
Species: Mouse, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 100 mg/kg body weight  
Result: Effects on fertility

Effects on foetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3.000 mg/kg body weight  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1.000 mg/kg body weight  
Result: No teratogenic effects

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Hydrochlorothiazide:**

Target Organs : Kidney, Parathyroid gland  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Olmesartan:**

Species : Rat  
NOAEL : 2.000 mg/kg  
Application Route : Oral  
Exposure time : 24 Months  
Remarks : No significant adverse effects were reported

**Hydrochlorothiazide:**

# Olmesartan / Hydrochlorothiazide Formulation

Version 3.5      Revision Date: 09.04.2021      SDS Number: 402646-00013      Date of last issue: 10.10.2020  
Date of first issue: 07.01.2016

Species : Rat, male and female  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 2 yr  
Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female  
NOAEL : 300 - 550 mg/kg  
Application Route : Oral  
Exposure time : 2 yr  
Remarks : No significant adverse effects were reported

Species : Dog  
: 50 - 200 mg/kg  
Application Route : Oral  
Exposure time : 9 Months  
Target Organs : Parathyroid gland

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Hydrochlorothiazide:

No aspiration toxicity classification

### Experience with human exposure

### Components:

#### Olmesartan:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: hypotension  
Remarks: May cause harm to the unborn child.  
Based on Human Evidence

#### Hydrochlorothiazide:

Eye contact : Symptoms: Eye irritation  
Ingestion : Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

## SECTION 12: Ecological information

### 12.1 Toxicity

### Components:

#### Hydrochlorothiazide:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 500 mg/l  
Exposure time: 48 h

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

## 12.2 Persistence and degradability

### Components:

#### Hydrochlorothiazide:

Stability in water : Hydrolysis: 46,2 %(96 h)

## 12.3 Bioaccumulative potential

No data available

## 12.4 Mobility in soil

No data available

## 12.5 Results of PBT and vPvB assessment

### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## 12.6 Other adverse effects

### Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.  
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number

Not regulated as a dangerous good

### 14.2 UN proper shipping name

Not regulated as a dangerous good

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

**14.3 Transport hazard class(es)**

Not regulated as a dangerous good

**14.4 Packing group**

Not regulated as a dangerous good

**14.5 Environmental hazards**

Not regulated as a dangerous good

**14.6 Special precautions for user**

Not applicable

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code**

Remarks : Not applicable for product as supplied.

**SECTION 15: Regulatory information****15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**15.2 Chemical safety assessment**

A Chemical Safety Assessment has not been carried out.

**SECTION 16: Other information**

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Full text of H-Statements**

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated exposure.

**Full text of other abbreviations**

Acute Tox. : Acute toxicity

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ZA OEL : South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits

ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit

ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

# SAFETY DATA SHEET



## Olmesartan / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 1A	H360D
STOT RE 2	H373

### Classification procedure:

Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.



# SAFETY DATA SHEET



## Olmesartan / Hydrochlorothiazide Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	402646-00013	Date of first issue: 07.01.2016

---

ZA / EN